Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions
The funding scramble: countries desperately seek HIV finance solutions
Is HIV integration a response or a death sentence? Communities demand answers
Does six-monthly PrEP have a future following the collapse of global HIV funding?
Stepping into the AI-driven future of HIV prevention and care
Children born with HIV have persistent inflammation markers linked to heart disease
The US cuts challenge African funders and governments to provide new models of PrEP access
Conflicts and humanitarian crises create new HIV vulnerabilities
US funding cuts cause immediate drops in numbers testing and on HIV treatment
